A Phase 2 clinical trial evaluating setmelanotide in a patient population with Pseudohypoparathyroidism Type 1a (PHP1a) and obesity was recorded as enrolling by invitation on July 23, 2026.
The study, titled "Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)," is registered under identifier NCT07496463. It is listed as a Phase 2 trial on ClinicalTrials.gov.
According to the registry entry, the trial's current status is enrolling by invitation, meaning participants are being selected according to a predetermined process rather than through open recruitment. No results have been posted for this trial at this time, and no efficacy or safety outcomes have been reported.
Setmelanotide is an approved therapy, and this trial update reflects only the current enrollment status as recorded in the public registry. No additional trial details, such as enrollment numbers or estimated completion dates, were included in the available event data.
Readers interested in learning more about setmelanotide, including its approved uses and mechanism, can refer to the compound overview for further context.